Corvus Pharmaceuticals Inc (NAS:CRVS)
$ 4.9 0.35 (7.69%) Market Cap: 314.86 Mil Enterprise Value: 273.56 Mil PE Ratio: 0 PB Ratio: 24.75 GF Score: 37/100

Q2 2024 Corvus Pharmaceuticals Inc Earnings Call Transcript

Aug 06, 2024 / 08:30PM GMT
Release Date Price: $3 (+6.38%)
Operator

Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals second quarter 2024 business update and financial results conference call. (Operator Instructions)

It is now my pleasure to turn the call over to Zack Kubow of Real Chemistry. Please go ahead, sir.

Zack Kubow
Real Chemistry - IR

Thank you, Operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals second quarter 2024 business update and financial results conference call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; Jim Rosenbaum, Senior Vice President of Research; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. The executive team will open the call with some prepared remarks, followed by a question-and-answer period.

I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot